PRJNA376664
Homo sapiens Variation
BCR-ABL1 kinase domain sequence analysis has become an essential tool of management of Ph+ leukemia patients on tyrosine kinase inhibitors therapy and the Sanger sequencing is the technique commonly utilized for this purpose. We compared a laboratory developed nanopore-based BCR-ABL1 mutation test to a traditional Sanger sequencing-based method.